Key Segmentation
By Product
-
Devices
-
Surgical & Diagnostic Devices
-
Vision Care Devices
-
-
Drugs
-
OTC Drugs
-
Prescription Drugs
-
By Indication
-
Macular Degeneration
-
Glaucoma
-
Dry Eye Disease
-
Retinopathy
-
Uveitis
-
Macular Edema
-
Blepharitis
-
Cataract
-
Optic Neuropathy
-
Others
By Phase
-
Discovery Phase
-
Preclinical Phase
-
Clinical Phase
By Sponsor Type
-
Pharmaceutical / Biopharmaceutical Companies
-
Medical Device Companies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market is expected to grow at a CAGR of 6.62% from 2026 to 2035.
The Ophthalmic Clinical Trials Market was valued at USD 1.75 Billion in 2025.
Rising global prevalence of age-related macular degeneration, glaucoma, and inherited retinal dystrophies creating pharmaceutical development investment.
Macular Degeneration dominated the market with approximately 28% share in 2025.
North America dominated the Ophthalmic Clinical Trials Market in 2025.